GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » ROIC %

Square Pharmaceuticals (DHA:SQURPHARMA) ROIC %

: 22.80% (As of Dec. 2023)
View and export this data going back to . Start your Free Trial

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Square Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was 22.80%.

As of today (2024-04-19), Square Pharmaceuticals's WACC % is 10.49%. Square Pharmaceuticals's ROIC % is 21.05% (calculated using TTM income statement data). Square Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Square Pharmaceuticals ROIC % Historical Data

The historical data trend for Square Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROIC %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.24 23.07 24.48 23.56 19.94

Square Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.59 19.75 13.28 27.25 22.80

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Square Pharmaceuticals ROIC % Distribution

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's ROIC % falls into.



Square Pharmaceuticals ROIC % Calculation

Square Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROIC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=16710.584 * ( 1 - 22% )/( (60635.687 + 70097.623)/ 2 )
=13034.25552/65366.655
=19.94 %

where

Invested Capital(A: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=111757.869 - 2229.799 - ( 48892.383 - max(0, 3661.829 - 62347.728+48892.383))
=60635.687

Invested Capital(A: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=121816.305 - 2315.243 - ( 49403.439 - max(0, 4229.146 - 70487.117+49403.439))
=70097.623

Square Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=19151.248 * ( 1 - 20.54% )/( (69039.11 + 64437.574)/ 2 )
=15217.5816608/66738.342
=22.80 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=128168.217 - 2615.608 - ( 56513.499 - max(0, 4713.689 - 74802.672+56513.499))
=69039.11

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=135934.014 - 14617.721 - ( 56878.719 - max(0, 16706.414 - 78175.622+56878.719))
=64437.574

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Square Pharmaceuticals  (DHA:SQURPHARMA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Square Pharmaceuticals's WACC % is 10.49%. Square Pharmaceuticals's ROIC % is 21.05% (calculated using TTM income statement data). Square Pharmaceuticals generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Square Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Square Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Square Pharmaceuticals (DHA:SQURPHARMA) Business Description

Traded in Other Exchanges
N/A
Address
Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.

Square Pharmaceuticals (DHA:SQURPHARMA) Headlines

No Headlines